TABLE 2.

Association between use of a specific antihypertensive medication class and incident dementia, compared with use of any other antihypertensive medication

	Dementia cases (%) in AHM class of interest	Dementia cases (%) in other AHM users	Crude model HR (95% CI)	Model 2 HR (95% CI)
ACEi	72/620 (11.6)	153/1287 (11.9)	1.09 (0.82–1.44)	1.07 (0.81–1.43)
ARB	37/390 (9.5)	188/1517 (12.4)	0.75 (0.53–1.07)	0.75 (0.53–1.07)
Beta-blocker	113/958 (11.8)	112/949 (11.8)	1.01 (0.78–1.31)	0.99 (0.76–1.30)
CCB	58/512 (11.3)	167/1395 (12.0)	0.96 (0.71–1.29)	0.92 (0.68–1.25)
Diuretic	117/974 (12.0)	108/933 (11.6)	1.07 (0.82–1.39)	1.03 (0.79–1.34)
Dihydropyridine CCB	37/399 (9.3)	188/1508 (12.5)	0.74 (0.52–1.05)	0.73 (0.51–1.04)
ATII-stimulating AHM	129/1180 (10.9)	96/727 (13.2)	0.81 (0.62–1.05)	0.80 (0.61–1.04)

Median follow-up: 10.4 years. Model 2: adjusted for age, sex, history of cardiovascular disease, and history of diabetes mellitus. The dementia cases (percentages) represent the number of participants with incident dementia from the participants using the AHM class of interest. ATII-stimulating AHM include ARBs, dihydropyridine CCBs and thiazide diuretics. ACEi, angiotensin-converting enzyme inhibitor; AHM, antihypertensive medication; ARB, angiotensin II receptor blocker; ATII, angiotensin II; CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio.